Formerly promising Pharmos nearing the end of its rope

Pharmos was an early contender in the field of nanomedicine, with a nanoemulsion drug delivery technology it was developing for osteoarthritis pain (see the March 6, 2007 LRNJ). We recently spoke with Colin Neill, the company's current CEO, to get an update. Colin told us that the company has signif...

This item has been archived in line with our efforts to keep our content relevant and up to date for our readership. For further assistance, please contact your Customer Success Manager or email Thank you!

Related Research

Pear Therapeutics doubles down on its digital therapeutic psychiatry portfolio with new asset acquisitions

Case Study | January 18, 2022

Pear Therapeutics is a digital therapeutics (DTx) company with multiple psychiatric products in commercial use. It was the first company to have a U.S. FDA–approved DTx, reSET. Since then, it has had two other products approved by the FDA: reSET‑O, and Somryst. All three products are commercially ... Not part of subscription

Akili Interactive is going public, expected to net USD 412 million and open up investment opportunities

News Commentary | February 01, 2022

The company will be going public through a special purpose acquisition company known as Social Capital Suvretta Holdings Corp. Akili Interactive will use the expected cash proceeds to support the rollout of their U.S. FDA‑approved pediatric ADHD therapeutic, EndeavorRx. With EndeavorRX, Akili is ... Not part of subscription

Otsuka Pharmaceutical and virtual reality (VR) startup Jolly Good partner on a JPY 5 billion deal to support psychiatric disorders

News Commentary | February 10, 2022

Otsuka inked an apparently strong JPY 5 billion deal with local VR developer Jolly Good to develop social skill training VR systems to socially rehabilitate patients with psychiatric disorders. Otsuka has a big psychiatry portfolio and values the impact of digital therapeutics (DTx), with a number ... Not part of subscription